Press Releases :: OPKO Health, Inc. (OPK)

Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health

Read the news release

Visit BioReference Health

Year

Category

Sep 11, 2018 8:30 am EDT

OPKO Comments on Continued Nasdaq Halt of Trading of Common Stock

Sep 7, 2018 8:11 pm EDT

OPKO Comments on SEC Complaint

Sep 4, 2018 8:00 am EDT

OPKO Initiates RAYALDEE Phase 2 Trial in Dialysis Patients

Aug 28, 2018 8:00 am EDT

OPKO Health’s BioReference Laboratories to Participate in the National Cancer Institute NCI-MATCH (Molecular Analysis for Therapy Choice) Phase II Clinical Trial

Aug 7, 2018 4:05 pm EDT

OPKO Health Reports Second Quarter 2018 Financial Results

Aug 3, 2018 1:29 pm EDT

OPKO Health Completes Enrollment in Global Phase 3 Study of Somatrogon (hGH-CTP) in Growth Hormone Deficient Children

Aug 2, 2018 8:00 am EDT

OPKO Health to Announce Second Quarter 2018 Financial Results on August 7, 2018

Jul 16, 2018 11:57 am EDT

OPKO Partner Vifor Fresenius Receives Marketing Approval for RAYALDEE in Canada

Jun 12, 2018 8:00 am EDT

GeneDx Announces Completion of 100,000 Exome Sequences

Jun 11, 2018 8:00 am EDT

OPKO Health Completes Enrollment in Phase 2b Study of OPK88003 to Treat Type 2 Diabetes and Obesity